CBT 509

Drug Profile

CBT 509

Alternative Names: 10B10 antibody; Anti CTLA-4 antibody - CBT Pharmaceuticals; CBT-509

Latest Information Update: 27 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crown Bioscience
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Mar 2018 10B10 antibody licensed to CBT Pharmaceuticals worldwide
  • 22 Mar 2018 CBT Pharmaceuticals plans to initiate clinical trials for Cancer by the end of 2018
  • 08 May 2017 Crown Bioscience and Jiangsu Qyun Bio-Pharmaceutical enter a research collaboration to develop 10B10 antibody
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top